Proteome Sciences PLC (PRM) - Net Assets
Based on the latest financial reports, Proteome Sciences PLC (PRM) has net assets worth GBX-8.58 Million GBX (≈ $-1.04K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX8.35 Million ≈ $1.02K USD) and total liabilities (GBX16.93 Million ≈ $2.06K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PRM asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX-8.58 Million |
| % of Total Assets | -102.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | -100.01% |
| 10-Year Change | -100.01% |
| Growth Volatility | 590.67 |
Proteome Sciences PLC - Net Assets Trend (1994–2024)
This chart illustrates how Proteome Sciences PLC's net assets have evolved over time, based on quarterly financial data. Also explore Proteome Sciences PLC assets under control for the complete picture of this company's asset base.
Annual Net Assets for Proteome Sciences PLC (1994–2024)
The table below shows the annual net assets of Proteome Sciences PLC from 1994 to 2024. For live valuation and market cap data, see Proteome Sciences PLC stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX-6.52 Million ≈ $-792.81 |
-112.52% |
| 2023-12-31 | GBX-3.07 Million ≈ $-373.04 |
-100.00% |
| 2022-12-31 | GBX69.26 Billion ≈ $8.43 Million |
-1.12% |
| 2021-12-31 | GBX70.04 Billion ≈ $8.52 Million |
+4.72% |
| 2020-12-31 | GBX66.88 Billion ≈ $8.14 Million |
+1.86% |
| 2019-12-31 | GBX65.66 Billion ≈ $7.99 Million |
+2.95% |
| 2018-12-31 | GBX63.78 Billion ≈ $7.76 Million |
-3.39% |
| 2017-12-31 | GBX66.02 Billion ≈ $8.03 Million |
-93.97% |
| 2016-12-31 | GBX1.09 Trillion ≈ $133.11 Million |
+1561.08% |
| 2015-12-31 | GBX65.86 Billion ≈ $8.01 Million |
-0.14% |
| 2014-12-31 | GBX65.96 Billion ≈ $8.03 Million |
+3.14% |
| 2013-12-31 | GBX63.95 Billion ≈ $7.78 Million |
+8342750.20% |
| 2012-12-31 | GBX-766.53K ≈ $-93.26 |
-123.24% |
| 2011-12-31 | GBX3.30 Million ≈ $401.39 |
-54.30% |
| 2010-12-31 | GBX7.22 Million ≈ $878.34 |
+178.14% |
| 2009-12-31 | GBX-9.24 Million ≈ $-1.12K |
-64.26% |
| 2008-12-31 | GBX-5.62 Million ≈ $-684.28 |
-159.77% |
| 2007-12-31 | GBX-2.17 Million ≈ $-263.42 |
-183.66% |
| 2006-12-31 | GBX2.59 Million ≈ $314.88 |
-67.04% |
| 2005-12-31 | GBX7.85 Million ≈ $955.24 |
-10.82% |
| 2004-12-31 | GBX8.80 Million ≈ $1.07K |
-25.67% |
| 2003-12-31 | GBX11.84 Million ≈ $1.44K |
+0.02% |
| 2002-12-31 | GBX11.84 Million ≈ $1.44K |
+371.94% |
| 2001-12-31 | GBX2.51 Million ≈ $305.27 |
-4.96% |
| 2000-12-31 | GBX2.64 Million ≈ $321.21 |
+2414.29% |
| 1999-12-31 | GBX105.00K ≈ $12.78 |
-89.82% |
| 1998-12-31 | GBX1.03 Million ≈ $125.44 |
-64.05% |
| 1997-12-31 | GBX2.87 Million ≈ $348.95 |
+793.46% |
| 1996-12-31 | GBX321.00K ≈ $39.06 |
-76.24% |
| 1995-12-31 | GBX1.35 Million ≈ $164.38 |
+600.37% |
| 1994-12-31 | GBX-270.00K ≈ $-32.85 |
0.00% |
| 1994-10-31 | GBX-270.00K ≈ $-32.85 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Proteome Sciences PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7632900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX2.95 Million | % |
| Other Comprehensive Income | GBX15.41 Million | % |
| Other Components | GBX51.47 Million | % |
| Total Equity | GBX-6.52 Million | 100.00% |
Proteome Sciences PLC Competitors by Market Cap
The table below lists competitors of Proteome Sciences PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Heavitree Brewery A
LSE:HVTA
|
$72.76K |
|
Sutton Harbour Holdings plc
LSE:SUH
|
$73.91K |
|
Winners
KQ:479960
|
$74.03K |
|
TC Unterhaltungselektronik AG
F:TCU
|
$74.66K |
|
Gem Diamonds Ltd
LSE:GEMD
|
$71.50K |
|
Argo Blockchain PLC
LSE:ARB
|
$70.15K |
|
Walker Crips Group PLC
LSE:WCW
|
$69.94K |
|
Seed Innovations Ltd
LSE:SEED
|
$69.75K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Proteome Sciences PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,066,000 to -6,516,000, a change of -3,450,000.
- Net loss of 3,406,000 reduced equity.
- Other comprehensive income increased equity by 10,712,000.
- Other factors decreased equity by 10,756,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-3.41 Million | -52.27% |
| Other Comprehensive Income | GBX10.71 Million | +164.4% |
| Other Changes | GBX-10.76 Million | -165.07% |
| Total Change | GBX- | % |
Book Value vs Market Value Analysis
This analysis compares Proteome Sciences PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-10-31 | GBX0.00 | GBX1.68 | x |
| 1994-12-31 | GBX0.00 | GBX1.68 | x |
| 1996-12-31 | GBX0.00 | GBX1.68 | x |
| 1997-12-31 | GBX0.04 | GBX1.68 | x |
| 1998-12-31 | GBX0.01 | GBX1.68 | x |
| 1999-12-31 | GBX0.00 | GBX1.68 | x |
| 2000-12-31 | GBX0.03 | GBX1.68 | x |
| 2001-12-31 | GBX0.03 | GBX1.68 | x |
| 2002-12-31 | GBX0.11 | GBX1.68 | x |
| 2003-12-31 | GBX0.10 | GBX1.68 | x |
| 2004-12-31 | GBX0.07 | GBX1.68 | x |
| 2005-12-31 | GBX0.06 | GBX1.68 | x |
| 2006-12-31 | GBX0.02 | GBX1.68 | x |
| 2007-12-31 | GBX-0.02 | GBX1.68 | x |
| 2008-12-31 | GBX-0.04 | GBX1.68 | x |
| 2009-12-31 | GBX-0.07 | GBX1.68 | x |
| 2010-12-31 | GBX0.04 | GBX1.68 | x |
| 2011-12-31 | GBX0.02 | GBX1.68 | x |
| 2012-12-31 | GBX0.00 | GBX1.68 | x |
| 2013-12-31 | GBX285.47 | GBX1.68 | x |
| 2014-12-31 | GBX282.13 | GBX1.68 | x |
| 2015-12-31 | GBX270.59 | GBX1.68 | x |
| 2016-12-31 | GBX274.36 | GBX1.68 | x |
| 2017-12-31 | GBX216.49 | GBX1.68 | x |
| 2018-12-31 | GBX211.92 | GBX1.68 | x |
| 2019-12-31 | GBX218.27 | GBX1.68 | x |
| 2020-12-31 | GBX222.90 | GBX1.68 | x |
| 2021-12-31 | GBX228.76 | GBX1.68 | x |
| 2022-12-31 | GBX221.00 | GBX1.68 | x |
| 2023-12-31 | GBX-0.01 | GBX1.68 | x |
| 2024-12-31 | GBX-0.02 | GBX1.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Proteome Sciences PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -69.70%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-66.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | 0.00% | 0.00% | 0.00x | 0.00x | GBX7.00K |
| 1994 | 0.00% | 0.00% | 0.00x | 0.00x | GBX7.00K |
| 1996 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-1.57 Million |
| 1997 | -52.20% | 0.00% | 0.00x | 1.19x | GBX-1.78 Million |
| 1998 | -179.53% | 0.00% | 0.00x | 1.84x | GBX-1.95 Million |
| 1999 | -1171.43% | 0.00% | 0.00x | 7.64x | GBX-1.24 Million |
| 2000 | -53.22% | 0.00% | 0.00x | 1.60x | GBX-1.67 Million |
| 2001 | -79.05% | 0.00% | 0.00x | 1.50x | GBX-2.23 Million |
| 2002 | -34.71% | -2397.66% | 0.01x | 1.17x | GBX-5.29 Million |
| 2003 | -57.25% | -3987.77% | 0.01x | 1.22x | GBX-7.97 Million |
| 2004 | -59.06% | -7125.02% | 0.01x | 1.17x | GBX-6.08 Million |
| 2005 | -87.84% | -42572.25% | 0.00x | 1.22x | GBX-7.68 Million |
| 2006 | -217.84% | -8233.93% | 0.01x | 2.47x | GBX-5.90 Million |
| 2007 | 0.00% | -1977.47% | 0.04x | 0.00x | GBX-5.04 Million |
| 2008 | 0.00% | -544.38% | 0.13x | 0.00x | GBX-4.06 Million |
| 2009 | 0.00% | -307.10% | 0.21x | 0.00x | GBX-3.09 Million |
| 2010 | 63.21% | 45.72% | 0.64x | 2.16x | GBX3.84 Million |
| 2011 | -119.96% | -387.53% | 0.09x | 3.31x | GBX-4.29 Million |
| 2012 | 0.00% | -368.93% | 0.17x | 0.00x | GBX-4.18 Million |
| 2013 | -0.01% | -147.39% | 0.00x | 24.26x | GBX-5.54 Billion |
| 2014 | -0.01% | -228.52% | 0.00x | 22.80x | GBX-5.96 Billion |
| 2015 | 0.00% | -144.42% | 0.00x | 18.73x | GBX-5.98 Billion |
| 2016 | 0.00% | -83.09% | 0.00x | 18.70x | GBX-6.49 Billion |
| 2017 | 0.00% | -73.88% | 0.00x | 17.73x | GBX-6.39 Billion |
| 2018 | 0.00% | -43.06% | 0.00x | 18.12x | GBX-6.26 Billion |
| 2019 | 0.00% | 3.22% | 0.00x | 17.70x | GBX-6.44 Billion |
| 2020 | 0.00% | 6.26% | 0.00x | 20.51x | GBX-6.58 Billion |
| 2021 | 0.00% | 1.41% | 0.00x | 20.05x | GBX-6.91 Billion |
| 2022 | 0.00% | 17.03% | 0.00x | 22.17x | GBX-6.83 Billion |
| 2023 | 0.00% | -48.59% | 0.44x | 0.00x | GBX-2.14 Million |
| 2024 | 0.00% | -69.70% | 0.53x | 0.00x | GBX-2.75 Million |
Industry Comparison
This section compares Proteome Sciences PLC's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $412,461,618
- Average return on equity (ROE) among peers: -155.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Proteome Sciences PLC (PRM) | GBX-8.58 Million | 0.00% | N/A | $71.69K |
| Abingdon Health Plc (ABDX) | $-115.66K | 0.00% | 0.00x | $259.67K |
| ANGLE plc (AGL) | $40.06 Million | -54.13% | 0.24x | $94.18K |
| genedrive plc (GDR) | $12.05 Million | -9.65% | 0.17x | $119.01K |
| Integrated Diagnostics Holdings PLC (IDHC) | $2.79 Billion | 50.55% | 1.23x | $325.54 Million |
| LungLife AI Inc (LLAI) | $20.13 Million | -36.98% | 0.09x | $15.48K |
| Oxford Biodynamics PLC (OBD) | $1.12 Million | -999.37% | 6.25x | $107.03K |
| Verici Dx Plc (VRCI) | $19.62 Million | -36.19% | 0.03x | $88.39K |
About Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in pla… Read more